Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-08-14 4:40 pm Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Nantahala Capital Management LLC | 1,862,250 3.540% | 627,250 (+50.79%) | Filing History |
| 2026-08-14 4:40 pm Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Caligan Partners LP | 3,163,866 5.900% | 1,528,843 (+93.51%) | Filing History |
| 2026-08-14 4:38 pm Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | RA Capital Management, L.P. | 3,483,099 6.300% | 1,027,444 (+41.84%) | Filing History |
| 2026-08-14 4:01 pm Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | BIOTECHNOLOGY VALUE FUND L P | 2,801,545 5.300% | 453,700 (+19.32%) | Filing History |
| 2026-08-14 10:39 am Sale | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | T. Rowe Price Investment Management, Inc. | 3,670 0.000% | -2,159,014 (-99.83%) | Filing History |
| 2026-08-14 09:00 am Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Avoro Capital Advisors LLC | 2,333,333 4.440% | 923,333 (+65.48%) | Filing History |
| 2026-08-14 08:24 am Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Deep Track Capital, LP | 3,610,000 6.870% | 554,973 (+18.17%) | Filing History |
| 2026-08-13 4:06 pm Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Affinity Asset Advisors, LLC | 2,900,000 5.500% | 1,559,160 (+116.28%) | Filing History |
| 2026-08-07 11:04 am Purchase | 2026-07-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | FMR LLC | 5,737,966 10.800% | 637,750 (+12.50%) | Filing History |
| 2026-08-07 08:44 am Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | STATE STREET CORP STT | 2,889,287 5.500% | 2,889,287 (New Position) | Filing History |
| 2026-08-06 10:14 am Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | FMR LLC | 5,100,216 9.700% | 1,911,815 (+59.96%) | Filing History |
| 2026-07-27 4:25 pm Purchase | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | BlackRock, Inc. BLK | 3,415,731 6.500% | 3,415,731 (New Position) | Filing History |
| 2026-07-06 5:29 pm Sale | 2026-06-30 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Millennium Management LLC | 9,857 0.000% | -924,572 (-98.95%) | Filing History |
| 2026-06-18 4:29 pm Purchase | 2026-06-11 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Commodore Capital LP | 5,721,109 9.900% | 5,721,109 (New Position) | Filing History |
| 2026-06-05 10:13 am Purchase | 2026-05-29 | 13G | AVALO THERAPEUTICS INC PAR AVTX | FMR LLC | 3,188,401 6.100% | 308,920 (+10.73%) | Filing History |
| 2026-05-29 4:37 pm Purchase | 2026-05-22 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Deep Track Capital, LP | 3,055,027 5.810% | 3,055,027 (New Position) | Filing History |
| 2026-05-26 5:10 pm Purchase | 2026-05-22 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Point72 Asset Management, L.P. | 2,710,817 5.200% | 2,083,315 (+332.00%) | Filing History |
| 2026-05-15 6:41 pm Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | Logos Global Management LP | 1,675,000 3.200% | 390,000 (+30.35%) | Filing History |
| 2026-05-15 4:34 pm Purchase | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | RA Capital Management, L.P. | 2,455,655 9.900% | 516,590 (+26.64%) | Filing History |
| 2026-05-15 4:31 pm Sale | 2026-03-31 | 13G | AVALO THERAPEUTICS INC PAR AVTX | ORBIMED ADVISORS LLC | 475,165 2.100% | -712,135 (-59.98%) | Filing History |